렉시오 테라퓨틱스 (LXEO) 주가

렉시오 테라퓨틱스(LXEO)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $4.20 (+0.48%), 시가총액 $402.03M, 52주 범위 $2.70 ~ $10.63.

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with…

핵심 지표

• 현재가: $4.20 (+0.48%)
• 시가총액: $402.03M
• 52주 최저~최고: $2.70 ~ $10.63
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NAS

렉시오 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.

렉시오 테라퓨틱스 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 적극 매수 (4.6 / 5)

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 1.74
• 순이익률: 0.00%
• 영업이익률: 0.00%

자주 묻는 질문